These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24394867)

  • 101. Levodopa-responsive breathing discomfort in Parkinson's disease patients.
    Tambasco N; Murgia N; Nigro P; Paoletti FP; Romoli M; Brahimi E; Filidei M; Simoni S; Muzi G; Calabresi P
    J Neural Transm (Vienna); 2018 Jul; 125(7):1033-1036. PubMed ID: 29845438
    [TBL] [Abstract][Full Text] [Related]  

  • 102. A dynamical-systems model for Parkinson's disease.
    Connolly CI; Burns JB; Jog MS
    Biol Cybern; 2000 Jul; 83(1):47-59. PubMed ID: 10933237
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms.
    Iwaki H; Tagawa M; Iwasaki K; Kawakami K; Nomoto M
    J Neurol Sci; 2019 Jul; 402():145-152. PubMed ID: 31151065
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Evaluation of speech impairment in early stages of Parkinson's disease: a prospective study with the role of pharmacotherapy.
    Rusz J; Cmejla R; Růžičková H; Klempíř J; Majerová V; Picmausová J; Roth J; Růžička E
    J Neural Transm (Vienna); 2013 Feb; 120(2):319-29. PubMed ID: 22772465
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Breathing pattern in patients with Parkinson's disease.
    Vercueil L; Linard JP; Wuyam B; Pollak P; Benchetrit G
    Respir Physiol; 1999 Dec; 118(2-3):163-72. PubMed ID: 10647860
    [TBL] [Abstract][Full Text] [Related]  

  • 106. The effect of medication on vastus lateralis muscle activation patterns in Parkinson's disease patients.
    Nishikawa Y; Watanabe K; Takahashi T; Kimura H; Maruyama H
    J Electromyogr Kinesiol; 2018 Oct; 42():66-73. PubMed ID: 29960263
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Parkinson's disease: disturbed vestibular function and levodopa.
    Lithgow BJ; Shoushtarian M
    J Neurol Sci; 2015; 353(1-2):49-58. PubMed ID: 25899315
    [TBL] [Abstract][Full Text] [Related]  

  • 108. A Systematic Review and Bayesian Meta-Analysis of Acoustic Measures of Prosody in Parkinson's Disease.
    Fumel J; Bahuaud D; Weed E; Fusaroli R; Basirat A
    J Speech Lang Hear Res; 2024 Aug; 67(8):2548-2564. PubMed ID: 39018262
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Determinants of tapping speed in normal control subjects and subjects with Parkinson's disease: differing effects of brief and continued practice.
    Nutt JG; Lea ES; Van Houten L; Schuff RA; Sexton GJ
    Mov Disord; 2000 Sep; 15(5):843-9. PubMed ID: 11009189
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Detecting Effect of Levodopa in Parkinson's Disease Patients Using Sustained Phonemes.
    Pah ND; Motin MA; Kempster P; Kumar DK
    IEEE J Transl Eng Health Med; 2021; 9():4900409. PubMed ID: 33796418
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Speech defects of parkinsonian patients. Effects of levodopa therapy on speech intelligibility.
    Nakano KK; Zubick H; Tyler HR
    Neurology; 1973 Aug; 23(8):865-70. PubMed ID: 4737081
    [No Abstract]   [Full Text] [Related]  

  • 112. Autosomal dominant familial Parkinson disease: older onset of age, and good response to levodopa therapy.
    Hasegawa K; Kowa H
    Eur Neurol; 1997; 38 Suppl 1():39-43. PubMed ID: 9276200
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Pneumophonic coordination impairments in parkinsonian dysarthria: importance of aerodynamic parameters measurements.
    Moustapha SM; Alain G; Robert E; Bernard T; Mourtalla KM; Lamine G; François V
    West Afr J Med; 2012; 31(2):129-34. PubMed ID: 23208484
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Prolongation of QTc interval in patients with Parkinson's disease.
    Oka H; Mochio S; Sato H; Katayama K
    Eur Neurol; 1997; 37(3):186-9. PubMed ID: 9137930
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Levodopa versus non-levodopa brain language fMRI in Parkinson's disease.
    Arantes PR; Gobato HH; Davoglio BB; Barreiros MÂ; Felício AC; Barsottini OG; Andrade LA; Amaro Junior E
    Einstein (Sao Paulo); 2012; 10(2):171-9. PubMed ID: 23052452
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Improved Estimation of Parkinsonian Vowel Quality through Acoustic Feature Assimilation.
    Gaballah A; Parsa V; Cushnie-Sparrow D; Adams S
    ScientificWorldJournal; 2021; 2021():6076828. PubMed ID: 34335114
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Defining Speech Subtypes in De Novo Parkinson Disease: Response to Long-term Levodopa Therapy.
    Rusz J; Tykalova T; Novotny M; Zogala D; Sonka K; Ruzicka E; Dusek P
    Neurology; 2021 Nov; 97(21):e2124-e2135. PubMed ID: 34607922
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Pulmonary function and medication effect in mild-stage subjects with Parkinson's disease.
    Oliveira RT; Santos FMD; Ramos AG; Seki KLM; Müller PT; Christofoletti G
    Arq Neuropsiquiatr; 2022 Dec; 80(12):1233-1238. PubMed ID: 36580961
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Work and power reduced in L-dopa naïve patients in the early-stages of Parkinson's disease.
    Lima LO; Cardoso F; Teixeira-Salmela LF; Rodrigues-de-Paula F
    Arq Neuropsiquiatr; 2016 Apr; 74(4):287-92. PubMed ID: 27097000
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Dysarthria and Quality of Life in neurologically healthy elderly and patients with Parkinson's disease.
    Lirani-Silva C; Mourão LF; Gobbi LT
    Codas; 2015; 27(3):248-54. PubMed ID: 26222941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.